Taysha Gene Therapies (TSHA)
(Real Time Quote from BATS)
$2.78 USD
+0.04 (1.46%)
Updated Aug 6, 2025 03:41 PM ET
After-Market: $2.79 +0.01 (0.36%) 4:06 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TSHA 2.78 +0.04(1.46%)
Will TSHA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TSHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSHA
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade
TSHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains?
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Other News for TSHA
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | TSHA ...
Taysha Gene Therapies (TSHA) Receives 'Buy' Rating from B of A Securities | TSHA Stock News
BofA Assigns Buy Rating to Taysha Gene Therapies (TSHA) with $8 Target | TSHA Stock News
Taysha Gene Therapies initiated with bullish view at BofA, here's why
Taysha Gene Therapies initiated with bullish view at BofA